Protalix BioTherapeutics
PLX
31 hedge funds and large institutions have $1.38M invested in Protalix BioTherapeutics in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.27% less ownership
Funds ownership: 0.73% → 0.45% (-0.27%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
60% less call options, than puts
Call options by funds: $20K | Put options by funds: $50K
73% less capital invested
Capital invested by funds: $5.05M → $1.38M (-$3.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$37K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$17.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.31K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$7.97K |
| 5 |
AA
Advisory Alpha
Holland,
Michigan
|
+$1.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$1.24M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$469K |
| 3 |
JGC
J. Goldman & Co
New York
|
-$112K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$39.5K |
| 5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$19.6K |
PLX Hedge Fund Activity: Q3 2019 in Review
31 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2019, worth a combined $1.38M — down 73% from $5.05M a quarter earlier.
Fund positioning in PLX was balanced in Q3 2019: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $37K. The largest seller was Fosun International, exiting entirely with an estimated $1.24M sold.
- 31 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $1.38M of Protalix BioTherapeutics stock for Q3 2019, down 73% quarter-over-quarter.
- 3 funds opened new Protalix BioTherapeutics positions in Q3 2019 and 3 closed out, a net change of 0 holders.
- The largest Protalix BioTherapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $37K added.
- The largest Protalix BioTherapeutics seller in Q3 2019 was Fosun International, an estimated $1.24M sold.
Based on aggregated 13F filings for Q3 2019.